N-acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation

Area of Science:

• Neuroscience
• Developmental Biology
• Biochemistry

Background:

• Myelination is crucial for cognitive function and preventing neuro-axonal damage in demyelinating diseases such as multiple sclerosis (MS).
• N-glycan branching, regulated by the metabolite GlcNAc, influences cell growth and differentiation by controlling cell surface receptor dynamics.
• Failure in remyelination contributes to irreversible damage in MS.

Purpose of the Study:

• To investigate the role of GlcNAc and N-glycan branching in primary myelination and myelin repair.
• To determine if GlcNAc administration can promote myelin repair and neuroprotection in models of demyelination.
• To explore the correlation between serum GlcNAc levels and demyelination in MS patients.

Main Methods:

• Assessed the impact of GlcNAc and N-glycan branching on oligodendrogenesis by measuring platelet-derived growth factor receptor-α (PDGFRα) endocytosis.
• Administered oral GlcNAc to lactating mice and their pups to evaluate effects on primary myelination.
• Induced demyelination in adult mice using cuprizone and assessed the therapeutic potential of oral GlcNAc on myelin repair and neuroprotection.
• Measured endogenous serum GlcNAc levels in MS patients and correlated them with imaging data.

Main Results:

• GlcNAc and N-glycan branching were found to promote oligodendrogenesis by inhibiting PDGFRα endocytosis.
• Oral GlcNAc administration to dams enhanced myelination in pups through breast milk.
• Genetic blockade of N-glycan branching impaired primary myelination.
• In cuprizone-induced demyelination, oral GlcNAc treatment prevented neuro-axonal damage and promoted myelin repair.
• MS patients showed an inverse correlation between serum GlcNAc levels and measures of demyelination and microstructural damage.

Conclusions:

• N-glycan branching and GlcNAc are critical regulators of both primary myelination and myelin repair.
• Oral GlcNAc demonstrates potential as a neuroprotective agent in demyelinating diseases, including MS.
• Targeting N-glycan branching pathways may offer novel therapeutic strategies for myelin repair.